Heparin‐induced thrombocytopenia (HIT) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2021 To 2032

 Heparin‐induced thrombocytopenia (HIT) is a potentially devastating immune-mediated adverse drug reaction caused by the emergence of antibodies that activate platelets in the presence of heparin. Despite thrombocytopenia, bleeding is rare; HIT is strongly associated with thromboembolic complications involving both the arterial and venous systems. Heparin is widely used for thromboprophylaxis or treatment in many clinical situations, including cardiovascular and orthopedic surgery and invasive procedures, acute coronary syndromes, venous thromboembolism, atrial fibrillation, peripheral occlusive disease, dialysis, and during extracorporeal circulation. Heparin‐induced thrombocytopenia (HIT) is the most important and frequent drug‐induced type of thrombocytopenia. It is associated with significant morbidity and mortality if unrecognized. Unfortunately, because thrombocytopenia is common in hospitalized patients and can be caused by various factors, HIT often remains unrecognized and undiagnosed. HIT develops in two distinct forms: type I and type II. HIT type I is a non‐immunologic response to heparin treatment, mediated by a direct interaction between heparin and circulating platelets causing platelet clumping or sequestration.

 

HIT type I affects up to 10% of patients, usually occurs within the first 48–72 h after initiation of heparin treatment and is characterized by mild and transient thrombocytopenia, often returning to normal within four days once the heparin is withdrawn.

 

The competitive landscape of Heparin‐induced thrombocytopenia (HIT) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Heparin‐induced thrombocytopenia (HIT) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Heparin‐induced thrombocytopenia (HIT) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Heparin‐induced thrombocytopenia (HIT) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

S. No    Asset               Company                                 Stage

1          VLX-1005         Veralox Therapeutics     Phase 1

2          argatroban        Mitsubishi Tanabe Pharma Corporation  Phase 2

3          Danaparoid Sodium       Aspen Global Incorporated        Phase 3

4          Angiomax (bivalirudin) anticoagulant       The Medicines Company            Phase 3

5          Desirudin (Iprivask™)    Canyon Pharmaceuticals, Inc.    Phase 2